Cancer in a Drop: Liquid biopsy insights from ESMO 2025

The Journal of Liquid Biopsy 2026 Open access

Read full text
Authors: Shivahamy Maheswaran, Canio Vito Martinelli, Diego de Miguel Perez, Erick Figueiredo Saldanha, Angelo Di Pasquale, Konstantinos Venetis, Nadia Ghazali, Pasquale Pisapia, Carolina Reduzzi, Roberto Borea
DOI: 10.1016/j.jlb.2026.100469
Cited by: 1
References: 22

Abstract

As our knowledge of liquid biopsy (LB) continues to grow and evolve, its significance across the cancer care continuum becomes increasingly clear (1). LB offers a non-invasive snapshot of disease status and serves as a promising tool for prognostic stratification. Minimal residual disease (MRD) assessment detection in lung cancer can help in providing prognostic information and a potential surrogate endpoint in oncology clinical trials (2–4). In this year’s European Society of Medical Oncology (ESMO) Annual Congress, LB was prominently featured with more than 350 abstracts and multiple dedicated oral sessions investigating its clinical utility across various solid tumor types.

Fields of Study & Subjects

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Esophageal Cancer Research and Treatment

Publication details

Journal / source
The Journal of Liquid Biopsy
Publisher
Elsevier BV
Volume
12
Pages
100469–100469
Publication date
17 April 2026
Language
EN